Tuesday, December 3

Healthcare

Neurocrine upped to overweight by Piper, sees '568 as still viable

08/30/20241 Min Read

Neurocrine overweight Piper sees upped viable

Previous ArticleCooperCompanies hits 52-week high on Q3 beat and guidance

Next Article Nuvectis gains on FDA’s orphan drug designation for cancer therapy